{"url":"https://lda.senate.gov/api/v1/filings/16786fdc-dff3-4efa-90dc-afe25d83fdf5/","filing_uuid":"16786fdc-dff3-4efa-90dc-afe25d83fdf5","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2025,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.senate.gov/filings/public/filing/16786fdc-dff3-4efa-90dc-afe25d83fdf5/print/","filing_document_content_type":"text/html","income":null,"expenses":"1390000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Michael Brzica, Vice President, Government Affairs","dt_posted":"2025-07-17T17:11:24-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"400 Interpace Parkway","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Parsippany","registrant_state":"NJ","registrant_zip":"07054","registrant":{"id":76695,"url":"https://lda.senate.gov/api/v1/registrants/76695/","house_registrant_id":36004,"name":"TEVA PHARMACEUTICALS USA, INC.","description":null,"address_1":"400 Interpace Parkway","address_2":null,"address_3":null,"address_4":null,"city":"Parsippany","state":"NJ","state_display":"New Jersey","zip":"07054","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"MICHAEL BRZICA","contact_telephone":"+1 202-258-9499","dt_updated":"2026-07-28T09:30:12.967343-04:00"},"client":{"id":169003,"url":"https://lda.senate.gov/api/v1/clients/169003/","client_id":12,"name":"TEVA PHARMACEUTICALS USA INC","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"NJ","state_display":"New Jersey","country":"US","country_display":"United States of America","ppb_state":"NJ","ppb_state_display":"New Jersey","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2007-08-14"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Use of Section viii statements in pharmaceutical labeling. FDAs approval of over-the-counter naloxone nasal spray. Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals. Implementation of the Inflation Reduction Act. Drug pricing proposals. Oversight and legislation to reform pharmacy benefit managers. Patent reform legislation. Proposals related to drug shortages. Reauthorization of the Pandemic and All Hazards Preparedness Act (PAHPA).","foreign_entity_issues":"Teva Pharmaceutical Industries, Ltd., identified on Registration (LD-1) as the indirect parent of Teva Pharmaceuticals USA Inc., has an interest in the issues listed.","lobbyists":[{"lobbyist":{"id":71789,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"BRZICA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":71266,"prefix":null,"prefix_display":null,"first_name":"COLMAN","nickname":null,"middle_name":"BRENDAN","last_name":"RAGAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":92535,"prefix":null,"prefix_display":null,"first_name":"BEENA","nickname":null,"middle_name":"S","last_name":"PATEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":11,"name":"Executive Office of the President (EOP)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":201,"name":"Homeland Security, Dept of (DHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAR","general_issue_code_display":"Tariff (miscellaneous tariff bills)","description":"A joint resolution terminating the national emergency declared to impose duties on articles imported from Canada (S.J.Res.37).","foreign_entity_issues":"Teva Pharmaceutical Industries, Ltd., identified on Registration (LD-1), as the indirect parent of Teva Pharmaceuticals USA, Inc., has an interest in the issues listed.","lobbyists":[{"lobbyist":{"id":71789,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"BRZICA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":92535,"prefix":null,"prefix_display":null,"first_name":"BEENA","nickname":null,"middle_name":"S","last_name":"PATEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":24,"name":"Commerce, Dept of (DOC)"},{"id":11,"name":"Executive Office of the President (EOP)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":22,"name":"U.S. Trade Representative (USTR)"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}